CA-RUBEDO/BEIERSDORF
Rubedo Life Sciences, a biotechnology company specializing in cellular senescence and anti-aging research, announced today a multi-year strategic partnership with German multinational beauty company Beiersdorf AG to develop innovative skin care products that address the effects of cellular aging. Beiersdorf additionally joins Rubedo as a strategic investor, having participated in its recent Series A financing round through its Oscar & Paul Corporate Venture Capital Fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423657886/en/
Rubedo Life Sciences scientists (Photo: Business Wire)
The partnership between Rubedo and Beiersdorf revolves around the exploration of novel compounds derived from Rubedo's extensive research programs, specifically targeting cellular senescence. Senescent cells accumulate with age and may contribute to age-related skin changes and pathologies. These compounds will be sourced from Rubedo's topical dermatology program, which have senolytic and anti-inflammatory properties.
As part of the partnership, Beiersdorf will conduct in vitro and in silico studies, and will conduct rigorous assessments of the identified compounds from Rubedo. The collaborative effort will culminate in in vivo human studies, aimed at validating the efficacy of the selected compounds in cosmetic skin care formulations. Rubedo shall be eligible to receive milestones and royalty payments.
“We are thrilled to announce our partnership with Beiersdorf, a recognized global leader in the cosmetics and skin care industry to develop new products that address skin aging,” said Marco Quarta, CEO of Rubedo Life Sciences. “For over 140 years, Beiersdorf has been a worldwide leader in skin care with global brands like NIVEA, Eucerin, and La Prairie. By combining Rubedo's expertise in cellular senescence with Beiersdorf's complementary expertise in skin care innovation, this partnership may revolutionize the landscape of skin care products, offering consumers new solutions that treat cellular aging for healthy and youthful-looking skin.”
“Our mission is to define the future of skincare through breakthrough innovation,” commented Beiersdorf CEO Vincent Warnery. “By partnering with Rubedo and combining cutting-edge expertise from both sides, we aim to redefine the standards in anti-age skincare.”
Rubedo's innovative approach to compound development, coupled with Beiersdorf's leading global brand platforms, is poised to set new standards in anti-aging skin care and develop new solutions for the multibillion face care market.
About Rubedo Life Sciences
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, visit www.rubedolife.com.
About Beiersdorf AG
Beiersdorf has stood for innovative, high-quality skin care products as well as pioneering skin research for more than 140 years. Leading international brands such as NIVEA, the world’s no. 1 skin care brand*, Eucerin (dermocosmetics), La Prairie (selective cosmetics), and Hansaplast/Elastoplast (plasters and wound care) are cherished by millions of people around the world day after day. Renowned brands such as Aquaphor, Coppertone, Chantecaille, Labello, 8x4, atrix, Hidrofugal, Maestro, and Florena round off our extensive portfolio in the Consumer Business Segment. Through the wholly owned affiliate tesa SE, Beiersdorf is also a globally leading manufacturer of technical adhesive tapes and provides self-adhesive solutions to industry, craft businesses, and consumers.
The Hamburg-based company generated sales of €9.5 billion as well as an operating result (EBIT) of €1.3 billion in fiscal year 2023. Beiersdorf has more than 21,000 employees worldwide, who are connected by shared core values, a strong corporate culture, and the Beiersdorf purpose Care Beyond Skin. With its business strategy, the company pursues a multi-year investment program focusing on competitive, sustainable growth. The program is consistent with the ambitious sustainability agenda, with which Beiersdorf is generating clear added value for consumers, society, and the environment.
* Source: Euromonitor International Limited; NIVEA by umbrella brand name in the categories Body Care, Face Care, and Hand Care; in retail value terms, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423657886/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CSC Digital Brand Services Announces Integration into CrowdStrike Falcon Adversary Intelligence’s Recon to Accelerate Detection and Enforcement Against Malicious Domains15.9.2025 23:27:00 CEST | Press release
CSC, the world’s leading enterprise-class domain registrar and online brand protection provider, announced today at Fal.Con 2025 a new integration of CSC’s domain security offerings with the CrowdStrike Falcon® cybersecurity platform. The integration with Recon, a core capability within Falcon Adversary Intelligence, enables organizations to accelerate the detection and takedown of malicious domains, reducing exposure to phishing, fraud, and brand abuse. As cybercrime reaches unprecedented levels, adversaries are increasingly exploiting digital assets, brands, and domain name system (DNS) infrastructure. Traditional defenses often overlook domain portfolios, leaving organizations vulnerable to spoofing, impersonation, and account takeovers. CSC and CrowdStrike are uniting to close this gap with a comprehensive solution that integrates advanced threat intelligence, rapid detection, and global enforcement. Through this integration, clients can: Leverage the Recon capability in Falcon Adv
Celonis Debuts at No. 3 on the 2025 Fortune Future 5015.9.2025 22:58:00 CEST | Press release
Celonis, a global leader in Process Mining, today announced it has been named to No. 3 on the 2025 Fortune Future 50 list, recognized among the world’s most promising companies poised for long-term growth. This marks the company’s first appearance on the list alongside a prestigious group of global innovators, and underscores its leadership in enabling successful AI and business transformation through Process Intelligence. Published annually in collaboration with the Boston Consulting Group, the Fortune Future 50 evaluates more than 2,000 public companies to identify those best positioned for sustained growth based on a proprietary system analyzing market potential, innovation, strategy, and investment in the future. “Being named to the Fortune Future 50 is powerful validation of the mission we’ve been on since day one - to make processes work for people, companies and the planet,” said Alex Rinke, co-CEO and co-founder of Celonis. “This is truly just the beginning of seeing how Proces
ElevenLabs-Powered Chroma Awards Opens Call For Submissions, With November 3 Deadline15.9.2025 15:00:00 CEST | Press release
Creator-Led Global AI Film, Music Video, and Games CompetitionUniting the Global AI Creative Community Chroma Awards, a groundbreaking AI Film, Music Video, and Games competition organized by ElevenLabs, the leading AI audio research and product company, announced today that submissions are open for its inaugural competition, with a November 3 deadline. Competition participants can access free trials of AI tools provided by sponsors starting today at https://pack.chromaawards.com/. The Chroma Awards was established with the mission to educate, empower, and spotlight the next generation of artists and showcase how AI can empower human creativity. The competition is organized by ElevenLabs and presented by Google Cloud, Freepik, fal, Dreamina AI, and CapCut. “Through this initiative we hope to unite creators, communities, and companies across the world to bring emerging technology and creative talent together in dialogue,” said Matty Shimura, Chroma Awards. “We’re incredibly grateful to
33 Innovators Join Morgan Stanley Inclusive & Sustainable Ventures Cohort15.9.2025 14:08:00 CEST | Press release
Accelerator’s expanded focus includes sustainable solutions and support for nonprofits 2025 cohort comprised of 33 early-stage innovators from the Americas and EMEA Five-month program to provide founders with $250,000 (£250,000), as well as mentorship and growth resources Morgan Stanley (NYSE: MS) today announced the global cohort of its Inclusive & Sustainable Ventures (MSISV). With founders from the Americas and Europe, the Middle East and Africa (EMEA), the 2025 MSISV cohort will support 29 startups in its Lab and four emerging nonprofits in its Collaborative, two in-house accelerators that will run over the next five months. Selected from thousands of applications, the 33 organizations will engage in a tailored entrepreneurship curriculum and receive mentorship and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners. The firm will invest $250,000 (£250,000 in EMEA) in each startup and provide each nonprofit with a $250,000 grant. “Morgan Stan
Helmholtz Munich and Parse Biosciences GigaLab Generate World’s Largest Human Lung Tissue Perturbation Atlas15.9.2025 14:00:00 CEST | Press release
Researchers aim to identify cellular circuit mechanisms and generate a dataset to fuel AI-driven foundational research of lung biology Helmholtz Munich and Parse Biosciences today announced a strategic partnership to generate the world’s broadest lung disease perturbation atlas, powered by Parse Biosciences’ GigaLab platform. Using a human lung ex-vivo tissue slice culture model from normal control donor lungs as well as explant lung tissues from patients with chronic lung disease, the study aims to identify novel targets and cell circuits in lung health and disease by characterizing disease-specific responses of cells to 900 pharmacological interventions. Prof Herbert Schiller, Director of Helmholtz Munich’s Precision Regenerative Medicine Research Unit, and a leading researcher on lung biology and disease, will head this ambitious initiative. “Measuring the effects of drug treatments at single cell level directly in human lung tissue at scale, will help us to find strategies that imp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom